MX362049B - Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica. - Google Patents
Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.Info
- Publication number
- MX362049B MX362049B MX2016016994A MX2016016994A MX362049B MX 362049 B MX362049 B MX 362049B MX 2016016994 A MX2016016994 A MX 2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A MX 362049 B MX362049 B MX 362049B
- Authority
- MX
- Mexico
- Prior art keywords
- htr
- type
- haematological malignancy
- diagnosing
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382249.2A EP2959904A1 (en) | 2014-06-27 | 2014-06-27 | Methods for treating, diagnosing and prognosing a haematological malignancy |
| PCT/EP2015/064571 WO2015197839A1 (en) | 2014-06-27 | 2015-06-26 | Methods for treating, diagnosing and prognosing a haematological malignancy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016994A MX2016016994A (es) | 2017-06-09 |
| MX362049B true MX362049B (es) | 2019-01-04 |
Family
ID=51162662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016994A MX362049B (es) | 2014-06-27 | 2015-06-26 | Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10195207B2 (enExample) |
| EP (2) | EP2959904A1 (enExample) |
| JP (2) | JP2017526629A (enExample) |
| KR (1) | KR102628235B1 (enExample) |
| CN (1) | CN106471373B (enExample) |
| AU (2) | AU2015279105B2 (enExample) |
| BR (1) | BR112016029562B1 (enExample) |
| CA (1) | CA2953272C (enExample) |
| DK (1) | DK3160472T3 (enExample) |
| ES (1) | ES2796056T3 (enExample) |
| IL (1) | IL249579B (enExample) |
| MX (1) | MX362049B (enExample) |
| RU (1) | RU2727418C2 (enExample) |
| WO (1) | WO2015197839A1 (enExample) |
| ZA (1) | ZA201700080B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562100B (zh) * | 2016-07-28 | 2021-07-20 | 江苏亚虹医药科技股份有限公司 | 多巴胺β-羟化酶(DBH)抑制剂和血清素受体(5-HT)拮抗剂用于治疗癌症的用途 |
| EP3348266A1 (en) * | 2017-01-16 | 2018-07-18 | Leukos Biotech, S.L. | Combination therapy for treating cancer |
| JP7002245B2 (ja) * | 2017-08-10 | 2022-01-20 | シスメックス株式会社 | 血液分析装置、血液分析方法およびプログラム |
| CN111886025A (zh) * | 2017-11-01 | 2020-11-03 | 新加坡国立大学 | 血清素能药物治疗病毒诱发的血小板减少症的用途 |
| AU2019208396B2 (en) | 2018-01-18 | 2024-11-14 | Leukos Biotech, S. L. | Apomorphine·palmitic acid cocrystal solid particle crystalline form |
| US11034751B1 (en) | 2018-01-30 | 2021-06-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using serotonin receptor inhibitors |
| CN111257558B (zh) * | 2020-01-19 | 2021-08-24 | 江苏省人民医院（南京医科大学第一附属医院） | 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| NL300886A (enExample) | 1962-11-23 | |||
| US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
| US3466325A (en) | 1965-04-30 | 1969-09-09 | Haessle Ab | 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof |
| DE1668055B2 (de) | 1967-03-10 | 1973-09-06 | Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt | Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung |
| GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| GB0202337D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Birmingham | Cancer treatment |
| KR20040055311A (ko) * | 2002-12-20 | 2004-06-26 | 주식회사 피앤아이 컨설팅 | 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템 |
| DE602004014254D1 (de) * | 2003-02-17 | 2008-07-17 | Bayer Healthcare Ag | Diagnostik- und therapie- verfahren von mit 5-ht1f rezeptor verbundenen haematologischen krankheiten |
| WO2008098351A1 (en) * | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| WO2008146101A1 (en) | 2007-06-01 | 2008-12-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ligands of hvem for treating hematologic malignancies and autoimmune diseases |
| NZ587292A (en) * | 2008-03-04 | 2012-09-28 | Pfizer Ltd | Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain |
| EP2433124B1 (en) * | 2009-05-19 | 2017-03-01 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| WO2015079439A1 (en) * | 2013-11-26 | 2015-06-04 | Technion Research And Development Foundation Limited | Neuronal modulation |
| US20150197839A1 (en) * | 2014-01-13 | 2015-07-16 | Maria Celeste Rellamas Tria | Forming conductive pattern using titania sol-gel |
-
2014
- 2014-06-27 EP EP14382249.2A patent/EP2959904A1/en not_active Withdrawn
-
2015
- 2015-06-26 ES ES15731945T patent/ES2796056T3/es active Active
- 2015-06-26 JP JP2016575341A patent/JP2017526629A/ja not_active Withdrawn
- 2015-06-26 WO PCT/EP2015/064571 patent/WO2015197839A1/en not_active Ceased
- 2015-06-26 EP EP15731945.0A patent/EP3160472B1/en active Active
- 2015-06-26 DK DK15731945.0T patent/DK3160472T3/da active
- 2015-06-26 BR BR112016029562-5A patent/BR112016029562B1/pt active IP Right Grant
- 2015-06-26 MX MX2016016994A patent/MX362049B/es active IP Right Grant
- 2015-06-26 RU RU2016147748A patent/RU2727418C2/ru active
- 2015-06-26 CN CN201580033662.1A patent/CN106471373B/zh active Active
- 2015-06-26 US US15/322,012 patent/US10195207B2/en active Active
- 2015-06-26 KR KR1020167035701A patent/KR102628235B1/ko active Active
- 2015-06-26 AU AU2015279105A patent/AU2015279105B2/en not_active Expired - Fee Related
- 2015-06-26 CA CA2953272A patent/CA2953272C/en active Active
-
2016
- 2016-12-15 IL IL249579A patent/IL249579B/en active IP Right Grant
-
2017
- 2017-01-04 ZA ZA2017/00080A patent/ZA201700080B/en unknown
-
2018
- 2018-12-11 US US16/216,701 patent/US11337984B2/en active Active
-
2020
- 2020-01-02 AU AU2020200010A patent/AU2020200010B2/en active Active
- 2020-02-07 JP JP2020019451A patent/JP6846551B2/ja active Active
- 2020-09-08 US US17/014,738 patent/US20210228593A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,199 patent/US20220323456A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016994A (es) | Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica. | |
| SG10201901076WA (en) | Methods of treating alzheimer's disease | |
| MX2021006560A (es) | Perfilado transcriptómico para prognosis de cáncer de mama. | |
| MY197809A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| MX2020002216A (es) | Metodos y composiciones para detectar y tratar endometriosis. | |
| MX2017004742A (es) | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. | |
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| MX2013011431A (es) | Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. | |
| WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
| MX2016009490A (es) | Ensayo novedoso para detectar periostina humana. | |
| NZ738100A (en) | Igfbp3 and uses thereof | |
| PH12019500675A1 (en) | Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer | |
| EP3693742A3 (en) | Methods of detecting prostate cancer | |
| WO2014071218A3 (en) | Biomarkers for breast cancer and methods of using same | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| WO2013132354A3 (en) | Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer | |
| MX2018009274A (es) | Cancer. | |
| WO2016027029A3 (fr) | Procédé pour déterminer le pronostic de survie d'un patient atteint d'un cancer du pancréas | |
| MX2016010948A (es) | Composiciones y metodos para identificar neoplasias de celulas b sensibles a terapia de reduccion de celulas b. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |